[3] [4] PCOS, GLP-1 Treatment and Menstrual Changes Polycystic ovary syndrome (PCOS) affects approximately 10% of women of reproductive age in the UK and is characterised by irregular periods, elevated androgens, and often insulin resistance
Mitoguardin-2-mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation
You have questions about adjusting your injection schedule for time zone changes
Whilst there is no established direct link between GLP-1 therapy and magnesium deficiency, selecting an appropriate supplement formparticularly one that minimises digestive discomfortcan support overall metabolic health
Less Common Side Effects (5-20%) Decreased appetite beyond the therapeutic effect affects some users more intensely than intended
The drugs also warn about side effects like pancreatitis, diabetic retinopathy, low blood sugar, kidney problems, allergic reactions and sudden gallbladder disease